Efficacy of chemotherapy of modified INP regimen for advanced non-small cell lung cancer

Objective To investigate the efficacy and toxicity of chemotherapy of modified INP regimen in treatment of advanced non-samll cell lung cancer and brain metastases.At the same time,to explore the relationship between the expression of β-tubulin-Ⅲ in NSCLC biopsies and sensitivity to this modified INP regimen.Methods The clinical data of 29 patients with advanced non-samll cell lung cancer admitted to The First Affiliated Hospital,Guangzhou Medical College were retrospectively analyzed.All the patients received modified INP regimen[ifosfamide(3 000 mg/m 2),iv,d1 + vinorelbine(25 mg/m 2),iv,d1 + cisplatin(60 mg/m 2),iv,divide into three days]every three weeks.The efficacy and toxicity of the modified INP were evaluated and all the data were analyzed via 2 independent sample tests.Results In initial treatment of patients,partial response(PR) was observed in 2 cases,stable disease(SD) in 6 cases and progression disease(PD) in 1 case,with an overall response rate(ORR) of 22.2 % and disease control rate(DCR) of 88.9%;in the retreatment of patients,PR was observed in 2 cases,SD in 14 cases,and PD in 4 cases,with an ORR of 10.0% and DCR of 80.0%.The total ORR and DCR were 13.8% and 82.8%.In brain metastases patients,PR was observed in 3 cases,SD in 4 cases,and PD in 3 cases,with an ORR of 30.0% and DCR of 70.0%.The toxicity was mild.Further,NSCLC patients with low β-tubulin-Ⅲ expression had better ORR than those with high expression.Conclusions The modified INP regimen is effective and well-tolerable for patients with advanced NSCLC,especially for brain metastases patients.The β-tubulin-Ⅲ expression is associated with the efficacy of this regimen probably.